PoPPI was a £3.4 million five-year collaborative programme, funded by the Engineering and Physical Sciences Research Council (EPSRC), between the

• ​University of Leeds
• University of Bristol
• Northern Institute for Cancer Research (Newcastle University)
• AstraZeneca
• Domainex

The programme, which started in Feb 2016 and concluded in Jan 2022, focused on the development of computational and chemical tools to classify protein-protein interactions (PPI) and use the resultant insight to synthesize molecules, which act as selective inhibitors and can be used as chemical probes. Understanding and modulating the PPIs will increase the knowledge of the underlying mechanisms of diseases, such as cancer and the neurodegenerative diseases, e.g. Alzheimer’s, Huntingdon’s and Parkinson’s.